Slow And Steady: Merck Advances COVID-19 Antiviral, Vaccine Programs

Q3 Revenue Rises Despite Pandemic’s Impacts On Vaccines Business

 
• By Mandy Jackson
  
old chronometer
Merck& Co.'s COVID-19 programs are not the fastest in the clinic but may have oral or one-time dosing advantages
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Earnings

More from Business